(Use Google Chrome or Mozilla Firefox to secure your place)
16 October 2019 | Online | Free-to-attend
Simplifying Global Complexity:
The Role of AI from Licensing to Regulatory Compliance
Simplifying Global Complexity:
The Role of AI from Licensing to Regulatory Compliance
The use of artificial intelligence (AI) across the pharmaceutical value chain was once theory. But it is quickly becoming the new reality for the industry.
Across the drug development process, AI is being used to uncover hidden insights, manage complex data, drive efficiencies and reduce growing costs. While we are hearing an increasing number of use cases across the R&D and clinical space, we’ve yet to hear comprehensive insight into how other core functions can benefit from this innovative technology.
In this one day event, we’ll bring together industry experts to show you exactly how to benefit from regulatory and competitive intelligence.
For both the regulatory function and business development and licensing, the volume of information to monitor is increasing. This is a problem as accurate and timely decisions are becoming even more critical for success. Across three sessions, we’ll offer up a deep dive into how AI can tackle your core challenges and drive your regulatory and business development strategy forward.
Sign up now to attend the complimentary event live!
SESSION 1 :
2pm-2:45pm [BST]
SPEAKER: Ian Greenberg, Executive Director, Corporate & Business Development at GlaxoSmithKline and Ketan Patel, Product Director - Portfolio, Licensing and Clinical, Clarivate Analytics
In this session, we will explore how AI can help you and your organization to:
- Utilize historical data to create models to identify paths and time to approval for drug development programs
- Use statistical modelling and data-driven evidence to value an internal portfolio, evaluate external assets and make comparisons
- Create forecast predictions for each aspect of drug development projects
- Speed up business development decision making using statistical models
- Understand the importance of early communication with Regulatory and other key functions to increase drug and program success
SESSION 2 :
3pm-3:45pm [BST]
SPEAKERS: Darin Oppenheimer, Executive Director for Regulatory Devices & Digital Health Solutions at Merck and Rick Finch, Global Head of Life Sciences Consulting Services, Clarivate Analytics
In this session, we will explore how AI can help you and your organization to:
- Identify and overcome potential obstacles early on to remove barriers to success
- Use regulatory intelligence to inform regulatory strategy, affairs and operations
- Uncover hidden opportunities to improve performance
- Understand and action key industry and regulatory trends
- Increase collaboration and communication with Business Development & Licensing and other key functions to increase drug and program success
SESSION 3 :
4pm-4:45pm [BST]
SPEAKERS: Rick Finch, Clarivate Analytics, Darin Oppenheimer, Merck and Ketan Patel, Clarivate Analytics
In this session, we bring together a panel of speakers to answer your burning questions about AI and how to drive greater collaboration across functions.
We'll recap the practical takeaways from the first two sessions and then have an in-depth discussion on some of the most pressing issues, queries and concerns about effective AI strategy across the drug life-cycle.
You will be able to join the conversation by sharing your questions and comments to ensure you gain actionable insights to successfully power your strategy forward.
Our Expert Speakers
Rick Finch
Global Head of Life Sciences Consulting Services
Clarivate Analytics
Darin Oppenheimer
Executive Director, Regulatory Devices & Digital Health Solutions
Merck
Ketan Patel
Product Director - Portfolio, Licensing and Clinical
Clarivate Analytics
Ian Greenberg
Executive Director, Corporate & Business Development
GlaxoSmithKline
In Partnership With :
©2024 IQPC. All rights reserved.
